Neomycin

Dermatitis

Volumn 21, Issue 1, 2010, Pages 3-7

  Sasseville, Denis ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXYSTREPTAMINE; ALLERGEN; AMIKACIN; AMINOGLYCOSIDE; BACITRACIN; BIAVAX; BUTIROSIN; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPLOID CELL VACCINE; EGG PROTEIN; EOLARIX; FLUVAX; FRAMYCETIN; GENTAMICIN; GENTAMICIN BONE CEMENT; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEXOSE; INFLUENZA VACCINE; KANAMYCIN; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; NEOMYCIN; NETILMICIN; ORAL POLIOMYELITIS VACCINE; ORIMUNE TRIVALENT; PAROMOMYCIN; POLIOMYELITIS VACCINE; POLYMYXIN B; RUBELLA VACCINE; SISOMICIN; STREPTIDINE; STREPTOMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VARILVIX; VIVAXIM;

ALLERGY; ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; AQUEOUS SOLUTION; BACILLUS SUBTILIS; CATARACT EXTRACTION; CHEMICAL STRUCTURE; CONTACT ALLERGY; CREAM; CROSS REACTION; DELAYED HYPERSENSITIVITY; DENTIST; DERMATITIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG SYNTHESIS; ERYTHRODERMA; EXTERNAL OTITIS; FACE; GASTROINTESTINAL ABSORPTION; HAND; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY REACTION; INTRACUTANEOUS TEST; JOINT PROSTHESIS; KNEE ARTHROPLASTY; LEG ULCER; NORTH AMERICA; NURSE; OCCUPATIONAL ECZEMA; OINTMENT; PAENIBACILLUS POLYMYXA; PATCH TEST; PHARMACIST; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN ALLERGY; SKIN DEFECT; VACCINATION; VACCINE PRODUCTION; VETERINARY MEDICINE;

ANTI-BACTERIAL AGENTS; DERMATITIS, ALLERGIC CONTACT; HUMANS; NEOMYCIN; PATCH TESTS;

EID: 76149128671     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.2310/6620.2009.09073     Document Type: Review

References (30)

1. Macdonald RH, Beck M. Neomycin: a review with particular reference to dermatologic usage. Clin Exp Dermatol 1983;8:249-58.
2. Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: epidemiology, responsible allergens and management. J Am Acad Dermatol 2008;58:1-21.
3. Baer RI, Ludwig JS. Allergic eczematous sensitization to neomycin. Ann Allergy 1952;10:136-7.
4. Prystowsky SD, Nonomura JH, Smith RW, Allen AM. Allergic hypersensitivity to neomycin. Relationship between patch test reactions and "use" tests. Arch Dermatol 1979;115:713-5.
5. Uter W, Rämsch C, Aberer W, et al. The European baseline series in 10 European countries, 2005/2006 - results of the European Surveillance System on Contact Allergies (ESSCA). Contact Dermatitis 2009;61:31-8.
6. Menezes de Padua CA, Schnuch A, Lessman H, et al. Contact allergy to neomycin sulfate: results of a multifactorial analysis. Pharmacoepidemiol Drug Saf 2005;14:725-33.
7. Zug KA, Warshaw EM, Fowler JF Jr, et al. Patch-test results of the North American Contact Dermatitis Group, 2005-2006. Dermatitis 2009;20:149-60.
8. Rietschel RL, Fowler JF Jr. Topical antimicrobials. In: Rietschel RL, Fowler JF Jr, editors. Fisher's contact dermatitis. 6th ed. Hamilton (ON): BC Decker; 2008. p. 210-29.
9. Andersen KE, White IR, Goossens A. Allergens from the standard series. In: Frosch PJ, Menné T, Lepoittevin JP, editors. Contact dermatitis. 4th ed. Berlin: Springer; 2006. p. 453-92.
10. Phillips DK. Neomycin sulfate. In: Guin JD, editor. Practical contact dermatitis. New York: McGraw-Hill Inc.; 1995. p. 167-77.
11. Epstein E. Contact dermatitis to neomycin with false negative patch tests: allergy established by intradermal and usage tests. Contact Dermatitis 1980;6:236-7.
12. Bjarnason B, Flosadó ttir E. Patch testing with neomycin sulfate. Contact Dermatitis 2000;43:295-302.
13. Kimura M, Kawada A. Contact sensitivity induced by neomycin with cross-sensitivity to other aminoglycoside antibiotics. Contact Dermatitis 1998;39:148-50.
14. Schorr WF, Ridgway HB. Tobramycin-neomycin cross-sensitivity. Contact Dermatitis 1977;3:133-7.
15. Förström L, Pirilä V. Cross-sensitivity within the neomycin group of antibiotics. Contact Dermatitis 1978;4:312.
16. Samsoen M, Metz R, Melchior E, Foussereau J. Cross-sensitivity between aminoside antibiotics. Contact Dermatitis 1980;6:141.
17. Carruthers JA, Cronin E. Incidence of neomycin and framycetin sensitivity. Contact Dermatitis 1976;2:269-70.
18. Rudzki E, Zakrzewski Z, Rebandel P, et al. Cross reactions between aminoglycoside antibiotics. Contact Dermatitis 1988;18:314-6.
19. Sood A, Taylor JS. Bacitracin: allergen of the year. Am J Contact Dermat 2003;14:3-4.
20. Grandinetti PJ, Fowler JF. Simultaneous contact allergy to neomycin, bacitracin and polymyxin. J Am Acad Dermatol 1990;23:646-7.
21. Van Ketel WG. Polymixine 8-sulfate and bacitracin. Contact Dermatitis Newsl 1974;15:445.
22. Ekelund AG, Möller H. Oral provocation in eczematous contact allergy to neomycin and hydroxyquinolines. Acta Derm Venereol (Stockh) 1969;49:422-6.
23. Menné T, Weismann K. Hämatogenes Kontaktekzem nach oraler Gabe von Neomyzin. Hautartzt 1984;35:319-20.
24. Bouffioux B, Heid E. Eczéma endogène à la néomycine. Nouv Dermatol 1990;9:25.
25. Morton CA, Evans CD, Douglas WS. Allergic contact dermatitis following subconjunctival injection of framycetin. Contact Dermatitis 1993;29:42-3.
26. Jacob SE, Barland C, ElSaie ML. Patch-test-induced "flare-up" reactions to neomycin at prior biopsy sites. Dermatitis 2008;19:E46-8.
27. Guin JD, Phillips D. Erythroderma from systemic contact dermatitis: a complication of systemic gentamicin in a patient with contact allergy to neomycin. Cutis 1989;43:564-7.
28. Haeberle M, Wittner B. Is gentamicin-loaded bone cement a risk for developing systemic allergic dermatitis? Contact Dermatitis 2009;60:176-7.
29. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. Am J Dis Child 1993;147:128-9.
30. Rietschel RL. Neomycin sensitivity and the MMR vaccine. JAMA 1981;245:571.